{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:42:39Z","timestamp":1790700159659,"version":"4.1.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,7,31]],"date-time":"2017-07-31T00:00:00Z","timestamp":1501459200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mycopathologia"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s11046-017-0182-0","type":"journal-article","created":{"date-parts":[[2017,7,31]],"date-time":"2017-07-31T08:58:03Z","timestamp":1501491483000},"page":"21-32","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Progress in Definition, Prevention and Treatment of Fungal Infections in Cystic Fibrosis"],"prefix":"10.1007","volume":"183","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3474-2857","authenticated-orcid":false,"given":"Carsten","family":"Schwarz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Hartl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Eickmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hector","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Benden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Durieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amparo","family":"Sole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Gartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos E.","family":"Milla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter James","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,31]]},"reference":[{"key":"182_CR1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/13693780802609604","volume":"47","author":"M Pihet","year":"2009","unstructured":"Pihet M, Carr\u00e8re J, Cimon B, et al. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis-a review. Med Mycol. 2009;47:387\u201397.","journal-title":"Med Mycol"},{"key":"182_CR2","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/mmy\/myw035","volume":"54","author":"S Ziesing","year":"2016","unstructured":"Ziesing S, Suerbaum S, Sedlacek L. Fungal epidemiology and diversity in cystic fibrosis patients over a 5-year period in a national reference center. Med Mycol. 2016;54:781\u20136.","journal-title":"Med Mycol"},{"key":"182_CR3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.prrv.2012.11.004","volume":"14","author":"R Wong","year":"2013","unstructured":"Wong R, Wong M, Robinson PD, Fitzgerald DA. Omalizumab in the management of steroid dependent allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis. Paediatr Respir Rev. 2013;14:22\u20134.","journal-title":"Paediatr Respir Rev"},{"key":"182_CR4","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ppul.22937","volume":"49","author":"K Tanou","year":"2014","unstructured":"Tanou K, Zintzaras E, Kaditis AG. Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence. Pediatr Pulmonol. 2014;49:503\u20137.","journal-title":"Pediatr Pulmonol"},{"key":"182_CR5","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/ppul.23612","volume":"52","author":"R Nov\u00e9-Josserand","year":"2017","unstructured":"Nov\u00e9-Josserand R, Grard S, Auzou L, et al. Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients. Pediatr Pulmonol. 2017;52:190\u20137.","journal-title":"Pediatr Pulmonol"},{"key":"182_CR6","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1399-3062.2009.00384.x","volume":"11","author":"M Berge","year":"2009","unstructured":"Berge M, Guillemain R, Boussaud V, et al. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients. Transplant Infect Dis. 2009;11:211\u20139.","journal-title":"Transplant Infect Dis"},{"issue":"Suppl 1","key":"182_CR7","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.3109\/13693786.2010.505203","volume":"48","author":"EM Billaud","year":"2010","unstructured":"Billaud EM, Guillemain R, Berge M, et al. Pharmacological considerations for azole antifungal drug management in cystic fibrosis lung transplant patients. Med Mycol. 2010;48(Suppl 1):S52\u20139.","journal-title":"Med Mycol"},{"key":"182_CR8","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1128\/AAC.01325-10","volume":"55","author":"RK Shields","year":"2011","unstructured":"Shields RK, Clancy CJ, Vadnerkar A, et al. Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy. Antimicrob Agents Chemother. 2011;55:1308\u201311.","journal-title":"Antimicrob Agents Chemother"},{"key":"182_CR9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/FTD.0b013e318275fe69","volume":"35","author":"J Brett","year":"2013","unstructured":"Brett J, Chong O, Graham GG, et al. Antifungal use and therapeutic monitoring of plasma concentrations of itraconazole in heart and lung transplantation patients. Ther Drug Monitor. 2013;35:133\u20136.","journal-title":"Ther Drug Monitor"},{"issue":"4","key":"182_CR10","first-page":"CD002204","volume":"11","author":"HE Elphick","year":"2016","unstructured":"Elphick HE, Southern KW. Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev. 2016;11(4):CD002204.","journal-title":"Cochrane Database Syst Rev"},{"key":"182_CR11","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","volume":"46","author":"TJ Walsh","year":"2008","unstructured":"Walsh TJ, Anaissie EJ, Denning DW. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327\u201360.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 4","key":"182_CR12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/ajt.12115","volume":"13","author":"N Singh","year":"2013","unstructured":"Singh N, Husain S, AST Infectious Diseases Community of Practice. Aspergillosis in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):228\u201341.","journal-title":"Am J Transplant"},{"key":"182_CR13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00277-013-1867-1","volume":"93","author":"S Mousset","year":"2014","unstructured":"Mousset S, Buchheidt D, Heinz W, et al. Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2014;93:13\u201332.","journal-title":"Ann Hematol"},{"key":"182_CR14","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1086\/657306","volume":"51","author":"TW Felton","year":"2010","unstructured":"Felton TW, Baxter C, Moore CB, et al. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. Clin Infect Dis. 2010;51:1383\u201391.","journal-title":"Clin Infect Dis"},{"key":"182_CR15","doi-asserted-by":"crossref","unstructured":"Meis JF, Chowdhary A, Rhodes JL, Fisher MC, Verweij PE. Clinical implications of globally emerging azole resistance in Aspergillus fumigatus. Philos Trans R Soc Lond B, Biol Sci. 2016;371(1709). pii: 20150460.","DOI":"10.1098\/rstb.2015.0460"},{"key":"182_CR16","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1128\/AAC.05077-11","volume":"56","author":"PR Burgel","year":"2012","unstructured":"Burgel PR, Baixench MT, Amsellem M, et al. High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob Agents Chemother. 2012;56:869\u201374.","journal-title":"Antimicrob Agents Chemother"},{"key":"182_CR17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1164\/rccm.201101-0134CI","volume":"184","author":"RM Kotloff","year":"2012","unstructured":"Kotloff RM, Thabut G. Lung transplantation. Am J Respir Crit Care Med. 2012;184:159\u201371.","journal-title":"Am J Respir Crit Care Med"},{"key":"182_CR18","doi-asserted-by":"crossref","first-page":"621342","DOI":"10.1155\/2014\/621342","volume":"2014","author":"TO Hirche","year":"2014","unstructured":"Hirche TO, Knoop C, Hebestreit H, et al. Practical guidelines: lung transplantation in patients with cystic fibrosis. Pulm Med. 2014;2014:621342.","journal-title":"Pulm Med"},{"key":"182_CR19","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/01.TP.0000437434.42851.d4","volume":"97","author":"ML Luong","year":"2014","unstructured":"Luong ML, Chaparro C, Stephenson A, et al. Pretransplant Aspergillus colonization of cystic fibrosis patients and the incidence of post-lung transplant invasive aspergillosis. Transplantation. 2014;97:351\u20137.","journal-title":"Transplantation"},{"key":"182_CR20","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1469-0691.2005.01128.x","volume":"11","author":"A Sol\u00e9","year":"2005","unstructured":"Sol\u00e9 A, Morant P, Salavert M, Pem\u00e1n J, Morales P. Valencia Lung Transplant Group. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect. 2005;11:359\u201365.","journal-title":"Clin Microbiol Infect"},{"key":"182_CR21","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s10096-007-0376-3","volume":"26","author":"M Iversen","year":"2007","unstructured":"Iversen M, Burton CM, Vand S, et al. Aspergillus infection in lung transplant patients: incidence and prognosis. Eur J Clin Microbiol Infect Dis. 2007;26:879\u201386.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"182_CR22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jcf.2007.06.006","volume":"7","author":"G Valenza","year":"2008","unstructured":"Valenza G, Tappe D, Turnwald D, et al. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J Cyst Fibros. 2008;7:123\u20137.","journal-title":"J Cyst Fibros"},{"key":"182_CR23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3109\/13693780802716532","volume":"48","author":"M Muthig","year":"2010","unstructured":"Muthig M, Hebestreit A, Ziegler U, Seidler M, M\u00fcller FMC. Persistence of Candida species in the respiratory tract of cystic fibrosis patients. Med Mycol. 2010;48:56\u201363.","journal-title":"Med Mycol"},{"key":"182_CR24","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/ppul.23302","volume":"50","author":"A Gileles-Hillel","year":"2015","unstructured":"Gileles-Hillel A, Shoseyov D, Polacheck I, et al. Association of chronic Candida albicans respiratory infection with a more severe lung disease in patients with cystic fibrosis. Pediatr Pulmonol. 2015;50:1082\u20139.","journal-title":"Pediatr Pulmonol"},{"key":"182_CR25","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1183\/09031936.01.00068901","volume":"18","author":"J Navarro","year":"2001","unstructured":"Navarro J, Rainisio M, Harms HK, et al. Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF. European epidemiologic registry of cystic fibrosis. Eur Respir J. 2001;18:298\u2013305.","journal-title":"Eur Respir J"},{"issue":"Suppl 1","key":"182_CR26","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.3109\/13693786.2010.503320","volume":"48","author":"SH Chotirmall","year":"2010","unstructured":"Chotirmall SH, Greene CM, McElvaney NG. Candida species in cystic fibrosis: a road less travelled. Med Mycol. 2010;48(Suppl 1):S114\u201324.","journal-title":"Med Mycol"},{"key":"182_CR27","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jcf.2016.01.004","volume":"15","author":"A Hector","year":"2016","unstructured":"Hector A, Kirn T, Ralhan A, et al. Microbial colonization and lung function in adolescents with cystic fibrosis. J Cystic Fibros. 2016;15:340\u20139.","journal-title":"J Cystic Fibros"},{"issue":"Suppl 7","key":"182_CR28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/1469-0691.12041","volume":"18","author":"AJ Ullmann","year":"2012","unstructured":"Ullmann AJ, Akova M, Herbrecht R, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect. 2012;18(Suppl 7):53\u201367.","journal-title":"Clin Microbiol Infect"},{"key":"182_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13225-014-0295-4","volume":"67","author":"M Lackner","year":"2014","unstructured":"Lackner M, de Hoog GS, Yang L, et al. Proposed nomenclature for\u00a0Pseudallescheria, Scedosporium and related genera. Fungal Divers. 2014;67:1\u201310.","journal-title":"Fungal Divers"},{"key":"182_CR30","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.healun.2005.12.011","volume":"25","author":"F Symoens","year":"2006","unstructured":"Symoens F, Knoop C, Schrooyen M, et al. Disseminated Scedosporium apiospermum infection in a cystic fibrosis patient after double-lung transplantation. J Heart Lung Transplant. 2006;25:603\u20137.","journal-title":"J Heart Lung Transplant"},{"issue":"Suppl 1","key":"182_CR31","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.3109\/13693786.2010.500627","volume":"48","author":"CC Blyth","year":"2010","unstructured":"Blyth CC, Middleton PG, Harun A, et al. Clinical associations and prevalence of Scedosporium spp. in Australian cystic fibrosis patients: identification of novel risk factors? Med Mycol. 2010;48(Suppl 1):S37\u201344.","journal-title":"Med Mycol"},{"issue":"Suppl 1","key":"182_CR32","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3109\/13693786.2010.503665","volume":"48","author":"A Paugam","year":"2010","unstructured":"Paugam A, Baixench MT, Demazes-Dufeu N, et al. Characteristics and consequences of airway colonization by filamentous fungi in 201 adult patients with cystic fibrosis in France. Med Mycol. 2010;48(Suppl 1):S32\u20136.","journal-title":"Med Mycol"},{"key":"182_CR33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jcf.2014.12.014","volume":"14","author":"L Sedlacek","year":"2015","unstructured":"Sedlacek L, Graf B, Schwarz C, et al. Prevalence of Scedosporium species and Lomentospora prolificans in patients with cystic fibrosis in a multicenter trial by use of a selective medium. J Cyst Fibros. 2015;14:237\u201341.","journal-title":"J Cyst Fibros"},{"key":"182_CR34","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1128\/AAC.05910-11","volume":"56","author":"M Lackner","year":"2012","unstructured":"Lackner M, de Hoog GS, Verweij PE, et al. Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species. Antimicrob Agents Chemother. 2012;56:2635\u201342.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 3","key":"182_CR35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/1469-0691.12465","volume":"20","author":"AM Tortorano","year":"2014","unstructured":"Tortorano AM, Richardson M, Roilides E, et al. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect. 2014;20(Suppl 3):27\u201346.","journal-title":"Clin Microbiol Infect"},{"key":"182_CR36","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1128\/AAC.01388-07","volume":"52","author":"P Troke","year":"2008","unstructured":"Troke P, Aguirrebengoa K, Arteaga C, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother. 2008;52:1743\u201350.","journal-title":"Antimicrob Agents Chemother"},{"key":"182_CR37","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jcf.2013.10.014","volume":"13","author":"J Holle","year":"2014","unstructured":"Holle J, Leichsenring M, Meissner PE. Nebulized voriconazole in infections with Scedosporium apiospermum\u2014case report and review of the literature. J Cyst Fibros. 2014;13:400\u20132.","journal-title":"J Cyst Fibros"},{"key":"182_CR38","doi-asserted-by":"crossref","unstructured":"Schwarz C, Thronicke A, Staab D, Tintelnot K. Scedosporium apiospermum: a fungal pathogen causing pneumonia in a patient with cystic fibrosis. JMM Case Rep. 2015;2(3).","DOI":"10.1099\/jmmcr.0.000061"},{"key":"182_CR39","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/INF.0000000000001130","volume":"35","author":"R Padoan","year":"2016","unstructured":"Padoan R, Poli P, Colombrita D, et al. Acute Scedosporium apiospermum endobronchial infection in cystic fibrosis. Pediatr Infect Dis J. 2016;35:701\u20132.","journal-title":"Pediatr Infect Dis J"},{"key":"182_CR40","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.mmcr.2013.01.002","volume":"2","author":"NE Rolfe","year":"2013","unstructured":"Rolfe NE, Haddad TJ, Wills TS. Management of Scedosporium apiospermum in a pre- and post-lung transplant patient with cystic fibrosis. Med Mycol Case Rep. 2013;2:37\u20139.","journal-title":"Med Mycol Case Rep"},{"issue":"Suppl 2","key":"182_CR41","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/S0924-8579(08)70019-0","volume":"32","author":"A Sol\u00e9","year":"2008","unstructured":"Sol\u00e9 A. Invasive fungal infections in lung transplantation: role of aerosolised amphotericin B. Int J Antimicrob Agents. 2008;32(Suppl 2):S161\u20135.","journal-title":"Int J Antimicrob Agents"},{"key":"182_CR42","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ijantimicag.2016.12.015","volume":"49","author":"A Martin-Vicente","year":"2017","unstructured":"Martin-Vicente A, Guarro J, Capilla J. Does a triple combination have better activity than double combinations against multiresistant fungi? Experimental in vitro evaluation. Int J Antimicrob Agents. 2017;49:422\u20136.","journal-title":"Int J Antimicrob Agents"},{"key":"182_CR43","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1046\/j.1469-0691.2000.00089.x","volume":"6","author":"J Meletiadis","year":"2000","unstructured":"Meletiadis J, Mouton JW, Meis JF, Verweij PE. Combination chemotherapy for the treatment of invasive infections by Scedosporium prolificans. Clin Microbiol Infect. 2000;6:336\u20137.","journal-title":"Clin Microbiol Infect"},{"key":"182_CR44","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1128\/AAC.47.1.106-117.2003","volume":"47","author":"J Meletiadis","year":"2003","unstructured":"Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother. 2003;47:106\u201317.","journal-title":"Antimicrob Agents Chemother"},{"key":"182_CR45","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1128\/CMR.00039-07","volume":"21","author":"KJ Cortez","year":"2008","unstructured":"Cortez KJ, Roilides E, Quiroz-Telles F, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev. 2008;21:157\u201397.","journal-title":"Clin Microbiol Rev"},{"key":"182_CR46","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1439-0507.2003.00878.x","volume":"46","author":"IB Gosbell","year":"2003","unstructured":"Gosbell IB, Toumasatos V, Yong J, et al. Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery. Mycoses. 2003;46:233\u20136.","journal-title":"Mycoses"},{"key":"182_CR47","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10096-002-0877-z","volume":"22","author":"BP Howden","year":"2003","unstructured":"Howden BP, Slavin MA, Schwarer AP, Mijch AM. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis. 2003;22:111\u20133.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"182_CR48","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/j.1651-2227.2003.tb00636.x","volume":"92","author":"M Studahl","year":"2003","unstructured":"Studahl M, Backteman T, St\u00e5lhammar F, Chryssanthou E, Petrini B. Bone and joint infection after traumatic implantation of Scedosporium prolificans treated with voriconazole and surgery. Acta Paediatr. 2003;92:980\u20132.","journal-title":"Acta Paediatr"},{"key":"182_CR49","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1399-3062.2007.00203.x","volume":"9","author":"SY Tong","year":"2007","unstructured":"Tong SY, Peleg AY, Yoong J, et al. Breakthrough Scedosporium prolificans infection while receiving voriconazole prophylaxis in an allogeneic stem cell transplant recipient. Transpl Infect Dis. 2007;9:241\u20133.","journal-title":"Transpl Infect Dis"},{"key":"182_CR50","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/00365540600786564","volume":"39","author":"SV Bhat","year":"2007","unstructured":"Bhat SV, Paterson DL, Rinaldi MG, Veldkamp PJ. Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease: successful combination therapy with voriconazole and terbinafine. Scand J Infect Dis. 2007;39:87\u201390.","journal-title":"Scand J Infect Dis"},{"key":"182_CR51","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1399-3062.2007.00240.x","volume":"10","author":"JY Li","year":"2008","unstructured":"Li JY, Yong TY, Grove DI, Coates PT. Successful control of Scedosporium prolificans septic arthritis and probable osteomyelitis without radical surgery in a long-term renal transplant recipient. Transpl Infect Dis. 2008;10:63\u20135.","journal-title":"Transpl Infect Dis"},{"key":"182_CR52","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11046-008-9131-2","volume":"166","author":"MR Ananda-Rajah","year":"2008","unstructured":"Ananda-Rajah MR, Grigg A, Slavin MA. Breakthrough disseminated Scedosporium prolificans infection in a patient with relapsed leukaemia on prolonged voriconazole followed by posaconazole prophylaxis. Mycopathologia. 2008;166:83\u20136.","journal-title":"Mycopathologia"},{"key":"182_CR53","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jiac.2013.09.006","volume":"20","author":"K Uno","year":"2014","unstructured":"Uno K, Kasahara K, Kutsuna S, et al. Infective endocarditis and meningitis due to Scedosporium prolificans in a renal transplant recipient. J Infect Chemother. 2014;20:131\u20133.","journal-title":"J Infect Chemother"},{"key":"182_CR54","doi-asserted-by":"crossref","first-page":"E63","DOI":"10.3314\/mmj.55.E63","volume":"55","author":"M Nishimori","year":"2014","unstructured":"Nishimori M, Takahashi T, Suzuki E, et al. Fatal fungemia with Scedosporium prolificans in a patient with acute myeloid leukemia. Med Mycol J. 2014;55:E63\u201370.","journal-title":"Med Mycol J"},{"key":"182_CR55","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s12185-015-1752-x","volume":"101","author":"Y Ochi","year":"2015","unstructured":"Ochi Y, Hiramoto N, Takegawa H, et al. Infective endocarditis caused by Scedosporium prolificans infection in a patient with acute myeloid leukemia undergoing induction chemotherapy. Int J Hematol. 2015;101:620\u20135.","journal-title":"Int J Hematol"},{"key":"182_CR56","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1128\/AAC.01477-08","volume":"53","author":"MM Rodr\u00edguez","year":"2009","unstructured":"Rodr\u00edguez MM, Calvo E, Serena C, et al. Effects of double and triple combinations of antifungal drugs in a murine model of disseminated infection by Scedosporium prolificans. Antimicrob Agents Chemother. 2009;53:2153\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"182_CR57","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1093\/jac\/dkt282","volume":"68","author":"C Biswas","year":"2013","unstructured":"Biswas C, Sorrell TC, Djordjevic JT, et al. In vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogens. J Antimicrob Chemother. 2013;68:2842\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"182_CR58","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1099\/jmm.0.000019","volume":"64","author":"F Compain","year":"2015","unstructured":"Compain F, Botterel F, Sitterl\u00e9 E, et al. In vitro activity of miltefosine in combination with voriconazole or amphotericin B against clinical isolates of Scedosporium spp. J Med Microbiol. 2015;64:309\u201311.","journal-title":"J Med Microbiol"},{"key":"182_CR59","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/mmy\/myv064","volume":"53","author":"M Homa","year":"2015","unstructured":"Homa M, Galg\u00f3czy L, T\u00f3th E, et al. In vitro antifungal activity of antipsychotic drugs and their combinations with conventional antifungals against Scedosporium and Pseudallescheria isolates. Med Mycol. 2015;53:890\u20135.","journal-title":"Med Mycol"},{"key":"182_CR60","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/mmy\/myw029","volume":"54","author":"M Homa","year":"2016","unstructured":"Homa M, Galg\u00f3czy L, T\u00f3th E, et al. In vitro susceptibility of Scedosporium isolates to N-acetyl-l-cysteine alone and in combination with conventional antifungal agents. Med Mycol. 2016;54:776\u20139.","journal-title":"Med Mycol"},{"issue":"8708","key":"182_CR61","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/0140-6736(90)91721-L","volume":"336","author":"G Haase","year":"1990","unstructured":"Haase G, Skopnik H, Kusenbach G. Exophiala dermatitidis infection in cystic fibrosis. Lancet. 1990;336(8708):188\u20139.","journal-title":"Lancet"},{"key":"182_CR62","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1439-0507.2003.00830.x","volume":"46","author":"N Bakare","year":"2003","unstructured":"Bakare N, Rickerts V, Bargon J, Just-N\u00fcbling G. Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cystic fibrosis. Mycoses. 2003;46:19\u201323.","journal-title":"Mycoses"},{"issue":"Suppl 1","key":"182_CR63","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.3109\/13693786.2010.495731","volume":"48","author":"P Lebecque","year":"2010","unstructured":"Lebecque P, Leonard A, Huang D, et al. Exophiala (Wangiella) dermatitidis and cystic fibrosis\u2014prevalence and risk factors. Med Mycol. 2010;48(Suppl 1):S4\u20139.","journal-title":"Med Mycol"},{"key":"182_CR64","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jcf.2013.12.007","volume":"13","author":"N Kondori","year":"2014","unstructured":"Kondori N, Lindblad A, Welinder-Olsson C, Wenneras C, Gilljam M. Development of IgG antibodies to Exophiala dermatitidis is associated with inflammatory responses in patients with cystic fibrosis. J Cyst Fibros. 2014;13:391\u20139.","journal-title":"J Cyst Fibros"},{"key":"182_CR65","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3114\/sim.2008.61.15","volume":"61","author":"M Sudhadham","year":"2008","unstructured":"Sudhadham M, Prakitsin S, Sivichai S, et al. The neurotropic black yeast Exophiala dermatitidis has a possible origin in the tropical rain forest. Stud Mycol. 2008;61:145\u201355.","journal-title":"Stud Mycol"},{"key":"182_CR66","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1439-0507.2002.00779.x","volume":"45","author":"T Matos","year":"2002","unstructured":"Matos T, de Hoog GS, de Boer AG, de Crom I, Haase G. High prevalence of the neurotrope Exophiala dermatitidis and related oligotrophic black yeasts in sauna facilities. Mycoses. 2002;45:373\u20137.","journal-title":"Mycoses"},{"key":"182_CR67","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.funbio.2011.04.007","volume":"115","author":"P Zalar","year":"2011","unstructured":"Zalar P, Novak M, de Hoog GS, Gunde-Cimerman N. Dishwashers\u2014a man-made ecological niche accommodating human opportunistic fungal pathogens. Fungal Biol. 2011;115:997\u20131007.","journal-title":"Fungal Biol"},{"key":"182_CR68","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/BF02113255","volume":"151","author":"G Kusenbach","year":"1992","unstructured":"Kusenbach G, Skopnik H, Haase G, Friedrichs F, Dohmen H. Exophiala dermatitidis pneumonia in cystic fibrosis. Eur J Pediatr. 1992;151:344\u20136.","journal-title":"Eur J Pediatr"},{"key":"182_CR69","doi-asserted-by":"crossref","first-page":"42886","DOI":"10.1038\/srep42886","volume":"7","author":"L Kirchhoff","year":"2017","unstructured":"Kirchhoff L, Olsowski M, Zilmans K, et al. Biofilm formation of the black yeast-like fungus Exophiala dermatitidis and its susceptibility to antiinfective agents. Sci Rep. 2017;7:42886.","journal-title":"Sci Rep"},{"key":"182_CR70","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1128\/CMR.00003-11","volume":"24","author":"AL Colombo","year":"2011","unstructured":"Colombo AL, Padovan ACB, Chaves GM. Current knowledge of Trichosporon spp. and Trichosporonosis. Clin Microbiol Rev. 2011;24:682\u2013700.","journal-title":"Clin Microbiol Rev"},{"key":"182_CR71","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/JCM.00460-09","volume":"47","author":"PW Hickey","year":"2009","unstructured":"Hickey PW, Sutton DA, Fothergill AW, et al. Trichosporon mycotoxinivorans, a novel respiratory pathogen in patients with cystic fibrosis. J Clin Microbiol. 2009;47:3091\u20137.","journal-title":"J Clin Microbiol"},{"key":"182_CR72","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1128\/JCM.28.7.1616-1622.1990","volume":"28","author":"T Walsh","year":"1990","unstructured":"Walsh T. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol. 1990;28:1616\u201322.","journal-title":"J Clin Microbiol"},{"key":"182_CR73","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/clind\/15.5.781","volume":"15","author":"E Anaissie","year":"1992","unstructured":"Anaissie E, Gokaslan A, Hachem R, et al. Azole therapy for trichosporonosis: clinical evaluation of eight patients, experimental therapy for murine infection, and review. Clin Infect Dis. 1992;15:781\u20137.","journal-title":"Clin Infect Dis"},{"key":"182_CR74","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/sj.bmt.1702231","volume":"25","author":"B Erer","year":"2000","unstructured":"Erer B, Galimberti M, Lucarelli G, et al. Trichosporon beigelii: a life-threatening pathogen in immunocompromised hosts. Bone Marrow Transplant. 2000;25:745\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"182_CR75","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/01.mph.0000164865.70522.d7","volume":"27","author":"C Antachopoulos","year":"2005","unstructured":"Antachopoulos C, Papakonstantinou E, Dotis J, et al. Fungemia due to Trichosporon asahii in a neutropenic child refractory to amphotericin B. J Pediatr Hematol Oncol. 2005;27:283\u20135.","journal-title":"J Pediatr Hematol Oncol"},{"key":"182_CR76","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1128\/JCM.43.4.1818-1828.2005","volume":"43","author":"C Girmenia","year":"2005","unstructured":"Girmenia C, Pagano L, Martino B, et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol. 2005;43:1818\u201328.","journal-title":"J Clin Microbiol"},{"key":"182_CR77","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1128\/JCM.03309-13","volume":"52","author":"AV Shah","year":"2014","unstructured":"Shah AV, McColley SA, Weil D, Zheng X. Trichosporon mycotoxinivorans infection in patients with cystic fibrosis. J Clin Microbiol. 2014;52:2242\u20134.","journal-title":"J Clin Microbiol"},{"key":"182_CR78","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2466-13-61","volume":"13","author":"C Kr\u00f6ner","year":"2013","unstructured":"Kr\u00f6ner C, Kappler M, Grimmelt AC, et al. The basidiomycetous yeast Trichosporon may cause severe lung exacerbation in cystic fibrosis patients\u2014clinical analysis of Trichosporon positive patients in a Munich cohort. BMC Pulm Med. 2013;13:61.","journal-title":"BMC Pulm Med"},{"key":"182_CR79","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10096-007-0366-5","volume":"26","author":"C Rieger","year":"2007","unstructured":"Rieger C, Geiger S, Herold T, Nickenig C, Ostermann H. Breakthrough infection of Trichosporon asahii during posaconazole treatment in a patient with acute myeloid leukaemia. Eur J Clin Microbiol Infect Dis. 2007;26:843\u20135.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"182_CR80","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00705-08","volume":"53","author":"D Andes","year":"2009","unstructured":"Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009;53:24\u201334.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"182_CR81","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.3109\/13693786.2010.521522","volume":"48","author":"LW Leclair","year":"2010","unstructured":"Leclair LW, Hogan DA. Mixed bacterial-fungal infections in the CF respiratory tract. Med Mycol. 2010;48(Suppl 1):S125\u201332.","journal-title":"Med Mycol"},{"key":"182_CR82","first-page":"209","volume":"52","author":"M Montagna","year":"2011","unstructured":"Montagna M, Barbuti G, Paglionico F, et al. Retrospective analysis of microorganisms isolated from cystic fibrosis patients in Southern Italy, 2002\u20132010. J Prev Med Hyg. 2011;52:209\u201314.","journal-title":"J Prev Med Hyg"},{"issue":"166\u201376","key":"182_CR83","first-page":"e1","volume":"48","author":"Y Nagano","year":"2010","unstructured":"Nagano Y, Elborn JS, Millar BC, et al. Comparison of techniques to examine the diversity of fungi in adult patients with cystic fibrosis. Med Mycol. 2010;48(166\u201376):e1.","journal-title":"Med Mycol"},{"key":"182_CR84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/13693786.2013.792438","volume":"52","author":"L Masoud-Landgraf","year":"2013","unstructured":"Masoud-Landgraf L, Badura A, Eber E, et al. Modified culture method detects a high diversity of fungal species in cystic fibrosis patients. Med Mycol. 2013;52:1\u20138.","journal-title":"Med Mycol"},{"key":"182_CR85","unstructured":"Jensen RH. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment. Dan Med J. 2016;63(10). pii: B5288."},{"key":"182_CR86","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1164\/rccm.200601-071OC","volume":"174","author":"GM Verleden","year":"2006","unstructured":"Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2006;174:566\u201370.","journal-title":"Am J Respir Crit Care Med"},{"key":"182_CR87","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/ppul.21240","volume":"45","author":"V Jubin","year":"2010","unstructured":"Jubin V, Ranque S, Stremler Le bel N, Sarles J, Dubus JC. Risk factors for Aspergillus colonization and allergic bronchopulmonary aspergillosis in children with cystic fibrosis. Pediatr Pulmonol. 2010;45:764\u201371.","journal-title":"Pediatr Pulmonol"},{"key":"182_CR88","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jcf.2015.06.004","volume":"15","author":"D Peckham","year":"2016","unstructured":"Peckham D, Williams K, Wynne S, et al. Fungal contamination of nebuliser devices used by people with cystic fibrosis. J Cyst Fibros. 2016;15:74\u20137.","journal-title":"J Cyst Fibros"},{"issue":"2","key":"182_CR89","doi-asserted-by":"crossref","first-page":"e0171485","DOI":"10.1371\/journal.pone.0171485","volume":"12","author":"C Schwarz","year":"2017","unstructured":"Schwarz C, Brandt C, Antweiler E, et al. Prospective multicenter German study on pulmonary colonization with Scedosporium\/Lomentospora species in cystic fibrosis: epidemiology and new association factors. PLoS ONE. 2017;12(2):e0171485.","journal-title":"PLoS ONE"},{"key":"182_CR90","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1517\/14656566.2013.838217","volume":"14","author":"RH Drew","year":"2013","unstructured":"Drew RH, Townsend ML, Pound MW, Johnson SW, Perfect JR. Recent advances in the treatment of life-threatening, invasive fungal infections. Expert Opin Pharmacother. 2013;14:2361\u201374.","journal-title":"Expert Opin Pharmacother"},{"key":"182_CR91","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/QCO.0000000000000203","volume":"28","author":"NP Wiederhold","year":"2015","unstructured":"Wiederhold NP, Patterson TF. What\u2019s new in antifungals: an update on the in vitro activity and in vivo efficacy of new and investigational antifungal agents. Curr Opin Infect Dis. 2015;28:539\u201345.","journal-title":"Curr Opin Infect Dis"},{"key":"182_CR92","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1128\/AAC.00291-11","volume":"55","author":"M Miyazaki","year":"2011","unstructured":"Miyazaki M, Horii T, Hata K, et al. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrob Agents Chemother. 2011;55:4652\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"182_CR93","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1128\/AAC.05954-11","volume":"56","author":"T Shibata","year":"2012","unstructured":"Shibata T, Takahashi T, Yamada E, et al. T-2307 causes collapse of mitochondrial membrane potential in yeast. Antimicrob Agents Chemother. 2012;56:5892\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"182_CR94","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1345\/aph.1M218","volume":"43","author":"R Karwa","year":"2009","unstructured":"Karwa R, Wargo KA. Efungumab: a novel agent in the treatment of invasive candidiasis. Ann Pharmacother. 2009;43:1818\u201323.","journal-title":"Ann Pharmacother"},{"key":"182_CR95","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2217\/fmb.14.122","volume":"10","author":"N Mancini","year":"2015","unstructured":"Mancini N, Marrone L, Clementi N, et al. Adoptive T-cell therapy in the treatment of viral and opportunistic fungal infections. Future Microbiol. 2015;10:665\u201382.","journal-title":"Future Microbiol"},{"key":"182_CR96","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/S1473-3099(14)70828-X","volume":"14","author":"A Zumla","year":"2014","unstructured":"Zumla A, Memish ZA, Maeurer M, et al. Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options. Lancet Infect Dis. 2014;14:1136\u201349.","journal-title":"Lancet Infect Dis"},{"key":"182_CR97","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1128\/AAC.02132-12","volume":"57","author":"W Gottardi","year":"2013","unstructured":"Gottardi W, Debabov D, Nagl M. N-chloramines, a promising class of well-tolerated topical anti-infectives. Antimicrob Agents Chemother. 2013;57:1107\u201314.","journal-title":"Antimicrob Agents Chemother"},{"key":"182_CR98","first-page":"383","volume":"37","author":"CG Ammann","year":"2014","unstructured":"Ammann CG, Fille M, Hausdorfer J, et al. Influence of poly-N-acetylglucosamine in the extracellular matrix on N-chlorotaurine mediated killing of Staphylococcus epidermidis. New Microbiol. 2014;37:383\u20136.","journal-title":"New Microbiol"},{"key":"182_CR99","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1128\/AAC.02700-13","volume":"58","author":"DC Cora\u00e7a-Huber","year":"2014","unstructured":"Cora\u00e7a-Huber DC, Ammann CG, Fille M, et al. Bactericidal activity of N-chlorotaurine against biofilm-forming bacteria grown on metal disks. Antimicrob Agents Chemother. 2014;58:2235\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"182_CR100","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/jam.12474","volume":"116","author":"W Gottardi","year":"2014","unstructured":"Gottardi W, Klotz S, Nagl M. Superior bactericidal activity of N-bromine compounds compared to their N-chlorine analogues can be reversed under protein load. J Appl Microbiol. 2014;116:1427\u201337.","journal-title":"J Appl Microbiol"},{"key":"182_CR101","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/lam.12490","volume":"61","author":"R Arnitz","year":"2015","unstructured":"Arnitz R, Nagl M, Gottardi W. Comparison of the microbicidal activity of monochloramine and iodine. Lett Appl Microbiol. 2015;61:518\u201322.","journal-title":"Lett Appl Microbiol"},{"key":"182_CR102","doi-asserted-by":"crossref","first-page":"6454","DOI":"10.1128\/AAC.00957-15","volume":"59","author":"M Lackner","year":"2015","unstructured":"Lackner M, Binder U, Reindl M, et al. N-Chlorotaurine exhibits fungicidal activity against therapy-refractory Scedosporium species and Lomentospora prolificans. Antimicrob Agents Chemother. 2015;59:6454\u201362.","journal-title":"Antimicrob Agents Chemother"},{"key":"182_CR103","doi-asserted-by":"crossref","unstructured":"Gruber M, Moser I, Nagl M, Lackner M. Bactericidal and fungicidal activity of N-chlorotaurine is enhanced in cystic fibrosis sputum medium. Antimicrob Agents Chemother. 2017;61. pii: e02527\u201316.","DOI":"10.1128\/AAC.02527-16"}],"container-title":["Mycopathologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11046-017-0182-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-017-0182-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-017-0182-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T21:39:10Z","timestamp":1602625150000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11046-017-0182-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,31]]},"references-count":103,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["182"],"URL":"https:\/\/doi.org\/10.1007\/s11046-017-0182-0","relation":{},"ISSN":["0301-486X","1573-0832"],"issn-type":[{"value":"0301-486X","type":"print"},{"value":"1573-0832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,31]]}}}